Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation.
AID
Affinity
IgA
IgA nephropathy
Mouse model
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
07
11
2018
accepted:
10
04
2019
pubmed:
23
6
2019
medline:
21
4
2020
entrez:
23
6
2019
Statut:
ppublish
Résumé
IgA nephropathy (IgAN) often follows infections and features IgA mesangial deposition. Polymeric IgA deposits in the mesangium seem to have varied pathogenic potential, but understanding their pathogenicity remains a challenge. Most mesangial IgA1 in human IgAN has a hypogalactosylated hinge region, but it is unclear whether this is required for IgA deposition. Another important question is the role of adaptive IgA responses and high-affinity mature IgA antibodies and whether low-affinity IgA produced by innate-like B cells might also yield mesangial deposits. To explore the effects of specific qualitative variations in IgA and whether altered affinity maturation can influence IgA mesangial deposition and activate complement, we used several transgenic human IgA1-producing models with IgA deposition, including one lacking the DNA-editing enzyme activation-induced cytidine deaminase (AID), which is required in affinity maturation. Also, to explore the potential role of the IgA receptor CD89 in glomerular inflammation, we used a model that expresses CD89 in a pattern observed in humans. We found that human IgA induced glomerular damage independent of CD89. When comparing mice able to produce high-affinity IgA antibodies with mice lacking AID-enabled Ig affinity maturation, we found that IgA deposition and complement activation significantly increased and led to IgAN pathogenesis, although without significant proteinuria or hematuria. We also observed that hinge hypoglycosylation was not mandatory for IgA deposition. In a mouse model of IgAN, compared with high-affinity IgA, low-affinity innate-like IgA, formed in the absence of normal antigen-driven maturation, was more readily involved in IgA glomerular deposition with pathogenic effects.
Sections du résumé
BACKGROUND
IgA nephropathy (IgAN) often follows infections and features IgA mesangial deposition. Polymeric IgA deposits in the mesangium seem to have varied pathogenic potential, but understanding their pathogenicity remains a challenge. Most mesangial IgA1 in human IgAN has a hypogalactosylated hinge region, but it is unclear whether this is required for IgA deposition. Another important question is the role of adaptive IgA responses and high-affinity mature IgA antibodies and whether low-affinity IgA produced by innate-like B cells might also yield mesangial deposits.
METHODS
To explore the effects of specific qualitative variations in IgA and whether altered affinity maturation can influence IgA mesangial deposition and activate complement, we used several transgenic human IgA1-producing models with IgA deposition, including one lacking the DNA-editing enzyme activation-induced cytidine deaminase (AID), which is required in affinity maturation. Also, to explore the potential role of the IgA receptor CD89 in glomerular inflammation, we used a model that expresses CD89 in a pattern observed in humans.
RESULTS
We found that human IgA induced glomerular damage independent of CD89. When comparing mice able to produce high-affinity IgA antibodies with mice lacking AID-enabled Ig affinity maturation, we found that IgA deposition and complement activation significantly increased and led to IgAN pathogenesis, although without significant proteinuria or hematuria. We also observed that hinge hypoglycosylation was not mandatory for IgA deposition.
CONCLUSIONS
In a mouse model of IgAN, compared with high-affinity IgA, low-affinity innate-like IgA, formed in the absence of normal antigen-driven maturation, was more readily involved in IgA glomerular deposition with pathogenic effects.
Identifiants
pubmed: 31227634
pii: ASN.2018111089
doi: 10.1681/ASN.2018111089
pmc: PMC6622418
doi:
Substances chimiques
Antigens, CD
0
Fc(alpha) receptor
0
Immunoglobulin A
0
Receptors, Fc
0
AICDA (activation-induced cytidine deaminase)
EC 3.5.4.-
Cytidine Deaminase
EC 3.5.4.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1238-1249Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 by the American Society of Nephrology.
Références
Blood. 1999 Jun 15;93(12):4387-94
pubmed: 10361137
J Clin Invest. 1999 Jul;104(1):73-81
pubmed: 10393701
Immunol Lett. 1999 May 3;68(1):83-7
pubmed: 10397160
J Exp Med. 2000 Jun 5;191(11):1999-2009
pubmed: 10839814
Cell. 2000 Sep 1;102(5):553-63
pubmed: 11007474
J Immunol. 2001 Sep 1;167(5):2861-8
pubmed: 11509633
Science. 2002 Nov 15;298(5597):1424-7
pubmed: 12434060
J Immunol. 2003 May 1;170(9):4564-71
pubmed: 12707334
Kidney Int. 2003 Jun;63(6):2286-94
pubmed: 12753320
Clin Exp Nephrol. 2008 Feb;12(1):20-7
pubmed: 18175057
Kidney Int. 2008 May;73(10):1128-36
pubmed: 18322546
Arthritis Rheum. 2009 Dec;60(12):3734-43
pubmed: 19950285
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3064-9
pubmed: 20133609
J Exp Med. 2011 Jan 17;208(1):67-80
pubmed: 21220451
Nephrol Dial Transplant. 2011 Dec;26(12):3930-7
pubmed: 21459784
J Clin Invest. 2011 Oct;121(10):3991-4002
pubmed: 21881212
Kidney Int. 2012 May;81(9):833-43
pubmed: 22318424
Science. 2012 Mar 9;335(6073):1195-200
pubmed: 22345399
J Exp Med. 2012 Apr 9;209(4):793-806
pubmed: 22451718
J Am Soc Nephrol. 2012 Oct;23(10):1753-60
pubmed: 22956820
Clin Exp Immunol. 2012 Dec;170(3):333-41
pubmed: 23121674
Glycoconj J. 2013 Oct;30(7):633-40
pubmed: 23292036
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
Mucosal Immunol. 2014 Jul;7(4):948-57
pubmed: 24399151
Semin Immunopathol. 2014 Jul;36(4):431-42
pubmed: 24442210
J Am Soc Nephrol. 2015 Jul;26(7):1503-12
pubmed: 25694468
Ann N Y Acad Sci. 2015 Dec;1362:122-31
pubmed: 26062045
Nat Commun. 2015 Jul 06;6:7613
pubmed: 26146363
Immunity. 2015 Nov 17;43(5):884-95
pubmed: 26546282
J Am Soc Nephrol. 2016 Sep;27(9):2748-61
pubmed: 26825533
Front Immunol. 2016 Apr 12;7:117
pubmed: 27148252
PLoS One. 2016 Jul 20;11(7):e0159426
pubmed: 27437939
Nat Commun. 2016 Sep 06;7:12698
pubmed: 27596266
Immunity. 2016 Sep 20;45(3):471-482
pubmed: 27653600
Front Immunol. 2016 Sep 09;7:324
pubmed: 27667991
Kidney Int. 2017 Dec;92(6):1458-1468
pubmed: 28750925
Science. 2018 Apr 13;360(6385):223-226
pubmed: 29650674
Eur J Immunol. 1987 Mar;17(3):321-6
pubmed: 3569402
Kidney Int. 1985 Oct;28(4):666-71
pubmed: 3910914
J Clin Pathol. 1993 Jul;46(7):607-10
pubmed: 8157744
Clin Exp Immunol. 1994 Jan;95(1):35-41
pubmed: 8287607